Crinetics Pharmaceuticals Appoints New Chief Financial Officer

Story Highlights
Crinetics Pharmaceuticals Appoints New Chief Financial Officer

Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an announcement.

On February 24, 2025, Crinetics Pharmaceuticals announced the appointment of Tobin Schilke as Chief Financial Officer, effective February 28, 2025. Mr. Schilke brings over 25 years of global pharmaceutical experience, having previously transformed biotech companies into commercial organizations. His appointment is seen as pivotal as Crinetics prepares for its first commercial launch and advances its development pipeline. The move is expected to accelerate Crinetics’ growth objectives and create long-term value for stakeholders.

More about Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Its lead development candidate, paltusotine, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors, while atumelnant is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.

YTD Price Performance: -27.33%

Average Trading Volume: 838,078

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $3.47B

For detailed information about CRNX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App